Bristol researchers use gene editing to improve red blood cell transfusion compatibility
1 May 2018
Synthetic biologists from the School of Biochemistry and BrisSynBio have succeeded in generating lab-made red blood cells with rare blood group types, that could one day be used to help patients who cannot be matched with donor blood.
The provision of blood for patients who require repeated blood transfusions, as well as for individuals with rare blood types, presents an enormous challenge to transfusion services worldwide. While most people can safely receive a blood transfusion from donated blood, patients with blood disorders such as thalassemia or sickle cell disease require frequent transfusions. With repeated transfusion, patients eventually develop an immune response to all but the most specifically matched donor blood due to an incompatibility of minor blood group antigens.
Using CRISPR-Cas9 mediated gene editing technology, individual cell lines were created in which specific blood group genes were altered to prevent the expression of blood group proteins that can cause immune reactions. Building on this gene-editing approach, the team then went on to produce cells that combined the deletion of multiple blood groups in a single cell line that could be differentiated to generate functional novel red blood cells with extremely broad transfusion compatibility. Transfusions of red blood cells edited to improve compatibility could provide better treatments for those patients whose clinical needs are difficult to meet.
This study, published this week in the prestigious EMBO Molecular Medicine journal provides the first proof of principle demonstration that gene editing can be used in combination with laboratory culture of red blood cells, to generate rare or customised red blood cells for patients with specific needs. Whilst the authors are keen to stress the many challenging and technical obstacles that must be overcome before this approach could be translated into the clinic, the work does provide an exciting window into the possible applications of red blood cells produced from gene edited cell lines.
Dr. Ashley Toye Director of the Bristol NIHR BTRU said:
“Blood made using genetically edited cells could one day provide compatible transfusions for a group of patients for whom blood matching is difficult or impossible to achieve within the donor population. However, much more work will still be needed to produce blood cells suitable for patient use.”
The work was carried out by a team of scientists based at the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in red cell products, a research partnership between the University of Bristol and NHS Blood and Transplant in Bristol.
J. Hawksworth, T.J. Satchwell, M. Meinders, D.E. Daniels, F. Regan, N.M. Thornton, M.C. Wilson, J.G.G Dobbe, G.J. Streeska, K. Trakarnsanga, K. Heesom, D.J. Anstee, J. Frayne and A.M. Toye
The researchers are grateful for funding from the National Institute for Health Research (NIHR), NHS Blood and Transplant (NHSBT) R&D, EPSRC/BBRSC funded BrisSynBio Centre and the EPSRC SynBio Centre for Doctoral Training (CDT) with Defence Science and Technology Laboratory (DSTL) as an industrial partner.
NHS Blood and Transplant is a joint England and Wales Special Health Authority. We are responsible for ensuring a safe and efficient supply of blood and associated services to the NHS in England. We are also the organ donation organisation for the UK and are responsible for matching and allocating donated organs.
BrisSynBio is a multi-disciplinary research centre that focuses on the biomolecular design and engineering aspects of synthetic biology. It has been established as one of six Synthetic Biology Research Centres in the UK. BrisSynBio is funded predominantly by the BBSRC and EPSRC, and has broad range of academic, industrial and public-facing partners. BrisSynBio is part of the Bristol BioDesign Institute, one of the University of Bristol's seven Specialist Research Institutes.